ArticleTrends in molecular medicine2022
Deep learning for subtyping the Alzheimer's disease spectrum.
Michael F Romano, Vijaya B Kolachalama
Open access · greenAbstract readComment
In one paragraphArticle in Trends in molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
2 authors at 2 institutions in 1 country.
Michael F RomanoDepartment of Medicine, Boston University School of Medicine, Boston, MA, USA; Department of Medicine, St. Elizabeth's Medical Center, Brighton, MA, USA; Department of Medicine, Tufts University School of Medicine, Boston, MA, USA.
Vijaya B KolachalamaDepartment of Medicine, Boston University School of Medicine, Boston, MA, USA; Department of Computer Science and Faculty of Computing & Data Sciences, Boston University, Boston, MA, USA. Electronic address: vkola@bu.edu.
Boston University · USSt. Elizabeth's Medical Center · US
Funding
TBDU19AG068753 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Thor Stein · 2020 to 2026
$42.4MSouth Texas Alzheimer's Disease Research CenterP30AG066546 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Mohamad Habes · 2021 to 2026
$24.0MMRI, Genetics &Cognitive Precursors of AD &DementiaR01AG016495 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI AU, RHODA · 1999 to 2016
$12.5MTemporal Trends, Novel Imaging and Molecular Characterization of Preclinical and Clinical Alzheimer's Disease in the Framingham CohortsR01AG054076 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DECARLI, CHARLES, SESHADRI, SUDHA · 2016 to 2020
$12.3MMRI, Cognitive, Genetic & Biomarker Precursors of AD & Dementia in Young AdultsR01AG033040 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI AU, RHODA, SESHADRI, SUDHA · 2009 to 2019
$11.2MPrecision Brain Health Monitoring for Alzheimer's Disease Risk Detection in the Framingham Study: Black & AA Recruitment SupplementRF1AG072654 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI AU, RHODA, GOLDSTEIN, LEE E. · 2021 to 2023
$2.4MPlasma Amylin Impact on Cognitive Function and Brain Morphology in the Framingham Heart StudyR01AG049899 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI AU, RHODA, QIU, WEI QIAO WENDY · 2015 to 2019
$2.3MMechanisms of drug-coated balloon therapyR01HL159620 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KOLACHALAMA, VIJAYA B. · 2021 to 2024
$2.1MCognitive Heterogeneity in those with high Alzheimer's Disease RiskRF1AG062109 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI AU, RHODA · 2020 to 2021
$1.8MPrecision Brain Health Monitoring for Alzheimer's Disease Risk Detection in the Framingham StudyR01AG072654 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Rhoda Au, LEE E. GOLDSTEIN · 2025 to 2026
$1.1MCognitive heterogeneity in those with high Alzheimer's Disease RiskR56AG062109 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI AU, RHODA · 2018 to 2018
$517kPRISTINE: Pre-cancer histology identification of Endobronchial biopsies using deep learningR21CA253498 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BEANE, JENNIFER ELLEN, KOLACHALAMA, VIJAYA B. · 2020 to 2020
$424kNCI NIH HHS R21 CA253498NHLBI NIH HHS R01 HL159620NIA NIH HHS P30 AG066546NIA NIH HHS R01 AG016495NIA NIH HHS R01 AG033040NIA NIH HHS R01 AG049899NIA NIH HHS R01 AG054076NIA NIH HHS R01 AG072654NIA NIH HHS R56 AG062109NIA NIH HHS RF1 AG062109NIA NIH HHS RF1 AG072654NIA NIH HHS U19 AG068753NIDDK NIH HHS R43 DK134273
6 · The paper itselfAbstract
In a recent article from Cell Reports Medicine, Kwak et al. generate novel insights about subtyping cognitively impaired individuals based on structural imaging. Quantifying heterogeneity in Alzheimer's disease via subtyping could help us harness new disease-modifying therapies and improve patient care by providing a more targeted approach.
Indexed as
Alzheimer DiseaseDeep LearningHumansAlzheimer’s diseasecerebrospinal fluidmild cognitive impairmentMRIPETsubtyping
Identifiers
PMID34996710
PMCPMC10100785
OpenAlexW4205950264
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390